Reviewing her2 testing in recent breast cancer cases
Part of Cancer clinical trials.
This study looks at breast cancer cases in the Sohag area to learn more about HER2, a protein that helps doctors decide on treatment. If you were recently diagnosed, your medical information and tissue sample may be used to help improve understanding of breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with breast cancer in 2025 or 2026.
- Your tumor was tested for HER2, a protein that can affect cancer growth.
- There is enough tissue from your biopsy to be reviewed again.
- You have complete medical records, including follow-up visits.
- Your tissue sample is in good condition (not damaged or unusable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a test called HER2 IHC (a way to check for a protein called HER2 on tumor cells) in people with certain cancers: non-small cell lung cancer (NSCLC), biliary tract cancer (BTC), gynecological cancers (cervical, endometrial, ovarian), and urothelial cancer (UC). It aims to see how well the test works in different patients. You may join if you have enough stored tumor tissue from a biopsy or surgery done within the past 5 years.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial is looking at whether HER2, a protein linked to some cancers, is found in different gynecologic tumors. It tests stored tumor tissue from women in Brazil to learn more about this marker.
This study looks at genetic factors to understand why some people’s HER2-positive breast cancer responds better—or has more side effects—after treatment. Your info and possible past treatment history may help researchers improve how HER2 treatment is chosen and managed.
This trial studies a more precise way to measure HER2 levels in breast cancer tissue. It may help identify patients whose cancer is HER2-low or HER2-zero, so they can get more targeted treatment.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
Hear when a new HER2 Status in Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.